Last $0.27 USD
Change Today +0.0007 / 0.26%
Volume 372.1K
HEB On Other Exchanges
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - $0.55
52 Week Low
11/25/13 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma. Its products also include Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

39 Employees
Last Reported Date: 03/14/14
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.0M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $553.8K
Chief Medical Officer and Medical Director
Total Annual Compensation: $265.5K
Compensation as of Fiscal Year 2013.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx Biopharma Announces Earnings Results for the Six Months Ended June 30, 2014

Hemispherx Biopharma announced earnings results for the six months ended June 30, 2014. The net loss (including non-cash effects) was approximately $8,792,000 or $0.05 per share as compared to a net loss of $7,894,000 or $0.05 per share for the same six month period in 2013.

Hemispherx Biopharma, Inc. to Report Q2, 2014 Results on Aug 08, 2014

Hemispherx Biopharma, Inc. announced that they will report Q2, 2014 results After-Market on Aug 08, 2014

Hemispherx Biopharma, Inc. Announces a Strategic Alliance with Bioclones (Pty) Ltd to Develop Multiple Projects

Hemispherx Biopharma, Inc. announced a strategic alliance to develop multiple projects with Bioclones (Pty) Ltd. ('Bioclones'). On June 25, 2014, Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principle goals, there were initiating studies utilizing Ampligen(R) as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine, currently in clinical trials in Cape Town, including pre-clinical studies followed, potentially, by a Phase 1 clinical trial; seeking South African Medicine's Control Council approval to conduct trials using Alferon(R) to eradicate the HIV virus in patients highly responsive to anti-retroviral therapy (HAART); and initiating a joint effort to obtain commercial registration of both Ampligen(R) and Alferon(R) in the South African markets. The first clinical program builds on the Bioclones patented (US Patent 7,981,673 entitled "Process for the maturation of dendritic cells and a vaccine") therapeutic human dendritic cell (DC) cancer vaccination approach. This invention provides a method of producing mature DCs in vitro, which comprises the step of culturing the immature DCs, thereafter exposing said cells to tumor antigens before administration to patients. The team has successfully obtained the necessary Ethics approval to use Ampligen(R) as an adjuvant in the Bioclones pre-clinical cancer immunotherapy program utilizing patient derived samples. Pre-clinical studies will be directed towards the potential treatment of breast cancer in particular, followed by prostate cancer. These studies are part of the effort to develop patient-specific DC immunotherapy vaccines against breast cancer and prostate cancer, which elicit an immune response that will target and kill cancer cells. Human DCs matured with Ampligen(R) and transfected with autologous tumor-specific mRNA are designed to elicit a potent and autologous tumoricidal antigen-specific cytotoxic response to the cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.27 USD +0.0007

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $226.98 USD +0.39
AstraZeneca PLC 4,567 GBp +87.50
Baxter International Inc $74.98 USD +0.07
Medigene AG €4.46 EUR -0.016
Sarepta Therapeutics Inc $22.93 USD +0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 275.6x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 171.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at